Lung Cancer Europe shared on LinkedIn:
“The Biotech Act is a new EU law proposed by the European Commission in December 2025 to speed up health biotechnology in Europe. It would change the rules for clinical trials, introduce combined studies for medicines and diagnostic tests, and extend market protection for some biotechnology medicines.
On 12 October, our President Debra Montague and Vice President Angeliki Souri represented Lung Cancer Europe at the European Parliament Intergroup on Cancer and Rare Diseases’ Expert Dialogue on the EU Biotech Act in Brussels.
The dialogue focused on three connected priorities: a more supportive environment for clinical trials, stronger European research and innovation, and making sure people benefit from advances in treatment. Speakers called for simpler, faster and more proportionate trial rules, and EORTC – European Organisation for Research and Treatment of Cancer stressed that a one-size-fits-all approach does not suit every trial.
Debra and Angeliki also met MEP Vytenis Andriukaitis, the Parliament’s rapporteur on the Act for the Public Health Committee, and MEP Stine Bosse, Co-Chair of the Intergroup. They also spoke with Dr Denis Lacombe, Director General of EORTC.
We have published our position on the Act. We welcome its aim of faster, more competitive health biotechnology, but it will only help people with lung cancer if new treatments and tests reach them in every member state. We are asking the European Parliament and the Council for six changes, including biomarker testing people can actually get and a funded, structured role for patient organisations in governing the Act.
Our position draws on the European Patients’ Forum recommendations and adds what is specific to lung cancer.”
Other articles about EU Biotech Act on OncoDaily.
